News

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following...

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"...

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics...

Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026...

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both...

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today...

In the news release, PrimeC New Data to Be Presented at AD/PD™ 2026 Conference, issued 18-Mar-2026 by NeuroSense over PR Newswire, we are advised by the company that changes have been made. The...

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the...

Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new...

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense...

Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business...

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones &...

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass.,

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions...

New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd....

Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to...

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass., April 4, 2025 /PRNewswire/ --...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the...

Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business...

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated...

In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007),...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce...

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced...

Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval...

The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the...

The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry...

12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved...

NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical...

Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints...

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass., June 24, 2024...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces that it has received a notice of delisting from...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will...

PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- NeuroSense...

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update. Corporate Highlights from...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD)...

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass.

Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass., April 12, 2024 /PRNewswire/ -- NeuroSense...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a...

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended...

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock...

End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE,...

This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ -- NeuroSense...

A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP)...

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a...

Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial,...

Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...

- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass., Nov. 9, 2023...

Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik will...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...

In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing...

Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024 CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ --...

SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multiple sites across Europe in its...

Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...

Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...

Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar event. CAMBRIDGE, Mass., Sept. 6, 2023...

ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023...

Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in two upcoming conferences...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended March 31,...

96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023 CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/...

Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals NeuroSense's...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...

In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results...

Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik and...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO...

QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept...

PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023 CAMBRIDGE, Mass., Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....

Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....

Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian...

NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which...